Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology.
about
Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cellsA full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptorsThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsBeta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptorBeta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins.Autonomic control of blood pressure in mice: basic physiology and effects of genetic modification.Do low-affinity states of beta-adrenoceptors have roles in physiology and medicine?Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.The 'state' of beta-adrenoceptorsOverexpression of beta 1-adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A cardiostimulation: implications for 'putative' beta 4-adrenoceptor pharmacologyImpairment of the low-affinity state beta1-adrenoceptor-induced relaxation in spontaneously hypertensive ratsAltered β1-3-adrenoceptor influence on α2-adrenoceptor-mediated control of catecholamine release and vascular tension in hypertensive ratsDownregulation of propranolol-sensitive beta-adrenoceptor signaling after inhibition of nitric oxide synthesisChallenges in β(3)-Adrenoceptor Agonist Drug DevelopmentStress and cardiac beta adrenoceptors.Adrenergic and calcium modulation of the heart in stress: from molecular biology to function.Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates.Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout.Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.Chronic activation of the low affinity site of β1-adrenoceptors stimulates haemodynamics but exacerbates pressure-overload cardiac remodelling.Alpha 1-adrenoceptor pharmacome: alpha 1L-adrenoceptor and alpha 1A-adrenoceptor in the lower urinary tract.Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: Confronting the maze.Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricleUse of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human β1-adrenoceptor expressed in HEK-293 cells.Proliferation of the human urothelium is induced by atypical β1 -adrenoceptors.Metabolic responses to BRL37344 and clenbuterol in soleus muscle and C2C12 cells via different atypical pharmacologies and beta2-adrenoceptor mechanismsA study of antagonist affinities for the human histamine H2 receptor.Atypical beta-adrenergic effects on insulin signaling and action in beta(3)-adrenoceptor-deficient brown adipocytes.β3-adrenoceptors inhibit stimulated norepinephrine release in spontaneously hypertensive rats.Evidence against beta 3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta.Negative cooperativity across β1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation.Physiological antagonism between ventricular beta 1-adrenoceptors and alpha 1-adrenoceptors but no evidence for beta 2- and beta 3-adrenoceptor function in murine heartDetection of the secondary, low-affinity β1 -adrenoceptor site in living cells using the fluorescent CGP 12177 derivative BODIPY-TMR-CGP.Positive inotropic and lusitropic effects mediated via the low-affinity state of beta1-adrenoceptors in pithed rats.ALpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta.Atypical beta-adrenoceptors, different from beta 3-adrenoceptors and probably from the low-affinity state of beta 1-adrenoceptors, relax the rat isolated mesenteric artery.Atypical cardiostimulant beta-adrenoceptor in the rat heart: stereoselective antagonism by bupranolol but lack of effect by some bupranolol analogues.Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.
P2860
Q21093341-561FD88B-4F7B-4AF8-8663-B808071AE009Q28476391-CB2D2CDB-FBEA-4F58-BA91-BEA4B40C4B84Q30486707-4B5ACC26-C8F9-456F-885F-C87B6DE28AA1Q33838174-831F1A49-E98B-48C5-9D45-5C6B3A626EA6Q34042126-9F69B9AA-6D02-4D3B-AB5E-20B701846848Q34403963-B3E00918-ED85-4F06-81C3-9ED7C0947CF4Q34637468-2F3A426F-3387-4062-827C-8C587E1C1926Q34650019-3ABF1B32-9125-4924-B3D7-FB5F4D33848AQ34837191-8B106DBA-8CB8-47A4-A561-B0A7E47BC732Q35045673-F8644190-3CB2-47E3-8B68-17D1405EDBBFQ35046211-3B840827-9497-417A-9C3C-3C6D521E2BE0Q35047790-5929411F-1041-4CEA-A36D-5F769A6CC57BQ35486753-0818FCEF-D1F6-4906-B717-0C80A0133DA3Q35545763-85758DB2-A855-4D0A-83D9-E93728DCB115Q36327996-7D29789C-25FB-49E3-A50A-3124C707F411Q36559968-4F356D18-58BF-43D6-ACCA-235ECFD4901BQ36827279-0E3B3FA8-9584-4BF8-B9BC-9BA60E882F80Q36880896-5194EE5B-475F-4488-92EF-8DE503482E97Q37023846-D7384B11-7DC9-4983-ABB8-BE7C37EB627BQ37129351-8181031C-483C-4141-A9F1-9A90F31FB62AQ37327391-1200C1BC-2D3E-477A-9CAA-77CFA96B8073Q37582994-8A746528-A925-4E07-AA93-48BC80E9BC42Q37939132-B63537B5-513E-468C-9F74-156A66B39C45Q38641723-4D61C9BF-B753-4F78-B1E8-59E7C0392463Q38738498-956D62EA-E2B2-45AB-A711-92804D743FB0Q39428983-6D399FDB-154D-4D06-A6B6-8848DDB256A8Q39970139-5970F3ED-92D1-4745-AE56-B730723B6A91Q39972489-8308A635-43E5-4AD2-9025-88922264E51AQ40141120-CA63F7C3-C069-4B81-8B4C-962D932BCA85Q40724615-74462B65-8B4D-48E3-A1E4-ED90481E25DEQ41856005-F91DC84C-DCE0-4CE5-8A34-F720F436E11BQ42049336-68D1B1D9-E0C8-4DD4-A178-43590B5EA8C2Q42149596-C37D7876-98DE-472A-8722-84CF20402EE3Q42544516-CBC07ECF-77F7-442E-9C8C-DD0D3ADCE66AQ42559814-ACEE5EB3-2003-456F-BC5F-0354CA345DF3Q43054865-906C228B-01E9-4965-A2FE-450E373B500BQ43262408-879E34FE-778F-478E-B3AA-EC705083F931Q43263250-85D7EDED-7AB0-4727-A250-C902973B7E55Q43263279-4B1DC2AE-3705-47CA-8ADE-E7031F2C366BQ43263681-E86A5F4B-D53A-4646-B6E7-3E6FE14EB1FC
P2860
Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Abolition of (-)-CGP 12177-evo ...... ta4-adrenoceptor pharmacology.
@ast
Abolition of (-)-CGP 12177-evo ...... ta4-adrenoceptor pharmacology.
@en
type
label
Abolition of (-)-CGP 12177-evo ...... ta4-adrenoceptor pharmacology.
@ast
Abolition of (-)-CGP 12177-evo ...... ta4-adrenoceptor pharmacology.
@en
prefLabel
Abolition of (-)-CGP 12177-evo ...... ta4-adrenoceptor pharmacology.
@ast
Abolition of (-)-CGP 12177-evo ...... ta4-adrenoceptor pharmacology.
@en
P2093
P356
P1476
Abolition of (-)-CGP 12177-evo ...... ta4-adrenoceptor pharmacology.
@en
P2093
P2888
P356
10.1007/S002100000336
P577
2001-01-01T00:00:00Z
P6179
1022341310